Biomedical Engineering Reference
In-Depth Information
and carboplatin in the treatment of PS 2 patients with chemotherapy-
naive advanced non-small cell lung cancer.
J Thorac Oncol, 2008.
3
(6):
p. 623-630.
116. Wheate, N.J., et al.,
The status of platinum anticancer drugs in the clinic
and in clinical trials.
Dalton Trans, 2010.
39
(35): p. 8113-8127.
117. Rademaker-Lakhai, J.M., et al.,
A phase I and pharmacological study of
the platinum polymer AP5280 given as an intravenous infusion once
every 3 weeks in patients with solid tumors.
Clin Cancer Res, 2004.
10
(10): p. 3386-3395.
118. Nowotnik, D.P. and E. Cvitkovic,
ProLindac (TM) (AP5346): A review of
the development of an HPMA DACH platinum polymer therapeutic.
Adv
Drug Deliv Rev, 2009.
61
(13): p. 1214-1219.
119. Yurkovetskiy, A.V. and R.J. Fram,
XMT-1001, a novel polymeric
camptothecin pro-drug in clinical development for patients with
advanced cancer.
Adv Drug Deliv Rev, 2009.
61
(13): p. 1193-1202.
120. Cheng, J.J., et al.,
Synthesis of linear, beta-cyclodextrin-based polymers
and their camptothecin conjugates.
Bioconjug Chem, 2003.
14
(5): p.
1007-1017.
121. Davis, M.E.,
Design and development of IT-101, a cyclodextrin-containing
polymer conjugate of camptothecin.
Adv Drug Deliv Rev, 2009.
61
(13):
p. 1189-1192.
122. Folkman, J.,
Tumor angiogenesis: therapeutic implications.
N Engl J Med,
1971.
285
(21): p. 1182-1186.
123. Satchi-Fainaro, R.,
Targeting tumor vasculature: reality or a dream?
J
Drug Target, 2002.
10
(7): p. 529-533.
124. Matsumura, Y. and H. Maeda,
A new concept for macromolecular
therapeutics in cancer chemotherapy: mechanism of tumoritropic
accumulation of proteins and the antitumor agent smancs.
Cancer Res,
1986.
46
(12 Pt 1): p. 6387-6392.
125. Joralemon, M.J., S. McRae, and T. Emrick,
PEGylated polymers for
medicine: from conjugation to self-assembled systems.
Chem Commun
(Camb), 2010.
46
(9): p. 1377-1393.
126. Winter, T.A., et al.,
Treatment of Crohn's disease with certolizumab pegol.
Expert Rev Clin Immunol, 2007.
3
(5): p. 683-694.
127. Ton, N.C., et al.,
Phase I evaluation of CDP791, a PEGylated di-Fab'
conjugate that binds vascular endothelial growth factor receptor 2.
Clin
Cancer Res, 2007.
13
(23): p. 7113-7118.
128. Einhorn, S. and D. Grander,
Why do so many cancer patients fail to
respond to interferon therapy?
J Interferon Cytokine Res, 1996.
16
(4):
p. 275-281.
Search WWH ::
Custom Search